Allergan (United Kingdom)

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid et al. · European Urology · 2013 · 401 citations

Urological Research, Urology, Voiding Dysfunction +5

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

Victor W. Νitti, Roger R. Dmochowski, Sender Herschorn et al. · The Journal of Urology · 2012 · 399 citations

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

Roger R. Dmochowski, Christopher R. Chapple, Victor W. Νitti et al. · The Journal of Urology · 2010 · 397 citations

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

Victor W. Νitti, Roger R. Dmochowski, Sender Herschorn et al. · The Journal of Urology · 2016 · 328 citations

Rates of visual field progression in clinical glaucoma care

Anders Heijl, P. Buchholz, Gunilla Norrgren et al. · Acta Ophthalmologica · 2012 · 221 citations · Full text